The world's population aged 65 and older is growing by an unprecedented 800,000 people a month and the global aging trend is expected to continue well into the 21st century. The range of diseases and chronic conditions associated with aging provides a breadth of attractive investment opportunities.
1 Westmount Square, Suite 800
In 2006, GeneChem raised its third focused fund to capitalise on the growth of the aging "Baby Boomer" segment of the population. With committed capital of $65M, the AgeChem Venture Fund L.P. sought to invest in companies developing therapeutics targeting diseases affecting the aging population, such as metabolic disorders (e.g. diabetes, obesity), cardiovascular diseases, cancers, diseases of the central nervous system (e.g. Alzheimer, Parkinson, insomnia), inflammatory diseases (e.g. rheumatoid arthritis, psoriasis) etc.